Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454116 · ClinicalTrials.gov registry record · Phase 2
A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00454116 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 106 participants.
The verdict
NCT00454116, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of 2 doses of ZACTIMA™ (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen.
Interventions
- DRUG FOLFIRI
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454116
The ClinicalTrials.gov registry entry for NCT00454116 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFIRI is the first listed.
NCT00454116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00454116 about?
NCT00454116 is a clinical study titled "A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients". The purpose of this study is to assess the efficacy and safety of 2 doses of ZACTIMA™ (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen.
What is the current status of trial NCT00454116?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2007-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00454116?
The interventions under investigation include: FOLFIRI (DRUG), Vandetanib (DRUG).
Who is sponsoring clinical trial NCT00454116?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.